Lung Fibrosis Drug Shows Early Biological Age Reduction in Trial

AI-developed drug for pulmonary fibrosis reduced biological age estimates in trial participants within weeks, but does not prove lifespan extension.

A Phase 2a clinical trial with 71 participants (42 analyzed) found Rentosertib, an AI-designed drug targeting idiopathic pulmonary fibrosis (IPF), reduced predicted biological age by approximately 3 years on average at week four for the 60 milligrams once-daily regimen compared to baseline. The split-dose regimen (30 milligrams twice daily) showed consistent reductions across all six proteomic biological age clocks but did not achieve the same magnitude of change. The drug altered 326 blood proteins, including fibrosis-linked markers like LTBP2, while reducing cellular senescence indicators. Crucially, the study did not measure lung function improvements or tissue senescent cells, and biological age reduction does not equate to extended lifespan.

This mechanism—modulating specific protein pathways associated with fibrosis and cellular aging—could theoretically lower long-term healthcare costs for IPF if later trials confirm clinical benefits. However, the current data only demonstrates a biological marker shift, not functional recovery. The trial’s future date (September 11, 2026) suggests this is still in early development.

What matters next: Phase 3 trials to confirm whether biological age changes translate to improved lung function and patient outcomes. Key caveats include the absence of direct lung function correlation, no tissue senescent cell measurement, and the fact that biological age reduction does not guarantee lifespan extension. This signal moves abundance potential for IPF care but remains early-stage.

Source: Lifespan.io